PedsCrit cover image

PARDS with Dr. Nadir Yehya and the Cribsiders--Part 3 Adjunctive Treatments, Disparities, and Next Steps

PedsCrit

00:00

The Risk Benefits of ECMO for Refactory ARDS

There's a lot of institutional variability and watch modalities people reach for. But ECMO, just like everything else, you will actually you will get better at it as you do more like surgery. And I think EOLIA was pretty good data. The adult trial had a 30% crossover rate that would have had very significant pvalue if those patients not gone to ECMO in the control arm. Like refractory hypoxamine and hypercarbia does work forrefactory ARDS. In pediatrics they're better than H1N1 because we are now an adult thing. They became an adult thing after NICU and then you pick up on this subsequent thing which is why

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app